NewAmsterdam Pharma Company N.V. Additional Paid in Capital, Common Stock
NewAmsterdam Pharma Company N.V. (NAMS) had Additional Paid in Capital, Common Stock of $1.49 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $1.49B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.46B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.43B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.40B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.49B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.46B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.43B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.40B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.38B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.36B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.30B 10-K · filed 2026-02-18 |
| 2024-09-30 | $829.40M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $821.61M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $807.01M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $590.77M 10-K · filed 2025-02-26 |
| 2022-12-31 | $555.63M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |